[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:higher-risk-myelodysplastic-syndrome":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":15,"states":16},"Higher Risk Myelodysplastic Syndrome",1,[7],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT04047641","Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",[11],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:20.384845Z","2026-05-05T02:43:27.571859Z",[],[]]